

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GSK | NYSE | USD | Real-time | |
GSKl | BATS Europe | GBP | Delayed | |
GLAXF | OTC Markets | USD | Delayed | |
GSK | London | GBP | Real-time | |
GSKN | Mexico | MXN | Delayed | |
GS70y | Frankfurt | EUR | Delayed | |
GS71 | TradeGate | EUR | Delayed | |
GS71 | Xetra | EUR | Delayed | |
GS71 | Frankfurt | EUR | Delayed | |
GSKm | Buenos Aires | ARS | Delayed | |
G1SK34 | B3 | BRL | Delayed |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Jonathan Richard Symonds | 66 | 2019 | Non-Executive Chairman |
Emma Natasha Walmsley | 56 | 2011 | CEO & Director |
Wendy Mira Becker | 60 | 2023 | Independent Non-Executive Director |
Charles A. Bancroft | 66 | 2020 | Senior Independent Non-Executive Director |
Julie Belita Brown | 63 | 2023 | CFO & Executive Director |
Vishal Sikka | 58 | 2022 | Independent Non-Executive Director |
Gavin Robert Screaton | 63 | 2025 | Independent Non-Executive Director |
Hal V. Barron | 63 | 2018 | Non-Executive Director |
Harry C. Dietz | 67 | 2022 | Independent Non-Executive Director |
Anne C. Beal | 63 | 2021 | Independent Non-Executive Director |
Elizabeth McKee Anderson | 68 | 2022 | Independent Non-Executive Director |
Tsun-Huei Lee | 61 | 2024 | Scientific & Medical Expert and Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review